Clinical translation of genotyping and haplotyping data: Implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping

Clinical Pharmacokinetics

Volumn 46, Issue 10, 2007, Pages 807-824

  Vizirianakis, Ioannis S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME; ERLOTINIB; GEFITINIB; IMATINIB; NEW DRUG; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL HERG; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB;

CHRONIC MYELOID LEUKEMIA; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GENETIC DATABASE; GENOTYPE; HAPLOTYPE; HEART ARRHYTHMIA; HUMAN; HUMAN GENOME PROJECT; MEDICAL INFORMATION SYSTEM; PHARMACOGENOMICS; PHARMACOTYPING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SOLID TUMOR; SUDDEN DEATH; TORSADE DES POINTES;

ANTINEOPLASTIC AGENTS; DATABASES, GENETIC; DRUG DELIVERY SYSTEMS; DRUG THERAPY; GENOTYPE; GUIDELINES AS TOPIC; HAPLOTYPES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MEDICAL INFORMATICS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL;

EID: 34548862923     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746100-00001     Document Type: Review

References (90)

1. Vizirianakis IS. From defining bioinformatics and pharmacogenomics to developing information-based medicine and pharmacotyping in healthcare. In: Gad SC, editor. Handbook of pharmaceutical biotechnology. New York: John Wiley & Sons, Inc., 2007: 201-28
2. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49
3. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-6
4. Müller M. Pharmacogenomics and the complexity of drug response. Int J Clin Pharmacol Ther 2003; 41: 231-40
5. Vizirianakis IS. Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? Pharmacogenomics 2005; 6: 701-11
6. Manasco PK, Rieser P, Renegar G, et al. Pharmacogenetics and the genetic basis of ADRs. In: Mann RD, Andrews EB, editors. Pharmacovigilance. West Sussex: John Wiley & Sons, Ltd, 2002: 516-53
7. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41: 101-21
8. Vizirianakis IS. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Curr Drug Deliv 2004; 1: 73-80
9. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Let 2004; 208: 1-33
10. Anderson JL, Carlquist JF, Horne BD, et al. Cardiovascular pharmacogenomics: current status, future prospects. J Cardiovasc Pharmacol Ther 2003; 8: 71-83
11. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2004; 4: 597-621
12. Ulrich CM, Robien K, Mcleod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912-20
13. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep 2005; 5: 101-8
14. Jain KK. Applications of AmpliChip™ CYP450. Mol Diagn 2005; 9: 119-27
15. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006; 27: 432-7
16. Mayo Clinic to provide pharmacogenomics test to indicate risks of side effects from irinotecan [editorial]. Personalized Medicine 2006; 3: 15-8
17. Traxler P. Tyrosine kinases as targets in cancer therapy: successes and failures. Expert Opin Ther Targets 2003; 7: 215-34
18. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nature Rev Cancer 2003; 3: 89-101
19. Graf T. Differentiation plasticity of hematopoietic cells. Blood 2002; 99: 3089-101
20. Hockenbery DM, Giedt CD, O'Neill JW, et al. Mitochondria and apoptosis: new therapeutic targets. Adv Cancer Res 2002; 85: 203-42
21. Fischer OM, Streit S, Hart S, et al. Beyond herceptin and Gleevec. Curr Opin Chem Biol 2003; 7: 490-5
22. Tsiftsoglou AS, Pappas IS, Vizirianakis IS. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther 2003; 100: 257-90
23. Million RP. Impact of genetic diagnostics on drug development strategy. Nat Rev Drug Discov 2006; 5: 459-62
24. Redell MS, Tweardy DJ. Targeting transcription factors in cancer: challenges and evolving strategies. Drug Discov Today: Technologies 2006; 3: 261-7
25. Capdeville R, Buchdunger E, Zimmermann J, et al. Clivec (STI-571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502
26. Cowan-Jacob SW, Guez V, Fendrich G, et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004; 4: 285-99
27. Suzuki T, Mitsudomi T, Hida T. The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. Personalized Medicine 2004; 1: 27-34
28. Golsteyn RM. The story of gefitinib, an EGFR kinase that works in lung cancer. Drug Discov Today 2004; 9: 587
29. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500
30. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39
31. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2005; 2: 554-61
32. American Association for Cancer Research. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent [media release]. Philadelphia (PA): American Association for Cancer Research, 2006 Sep 14. Available from URL: http://www.aacr.org/home/public-media/newsreleases.aspx? d=651 [Accessed 2007 Jul 26]
33. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44
34. Domen J. The role of apoptosis in regulating hematopoietic stem cell numbers. Apoptosis 2001; 6: 239-52
35. Tsiftsoglou AS, Pappas IS, Vizirianakis IS. The developmental program of murine erythroleukemia cells. Oncol Res 2003; 13: 339-46
36. Tagliafico E, Tenedini E, Manfredini R, et al. Identification of a molecular signature predictive to sensitivity to differentiation induction in acute myeloid leukemia. Leukemia 2006; 20: 1751-8
37. Nebert DW, Nebert LJ, Vesell ES. Pharmacogenomics and 'individualized drug therapy': high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361-70
38. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5: 645-56
39. Lindpaintner K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Discov 2002; 1: 463-9
40. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 2004; 25: 22-8
41. Yoo CB. Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50
42. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94
43. Voora D, McLeod HL, Eby C, et al. The pharmacogenetics of coumarin therapy. Pharmacogenomics 2005; 6: 503-13
44. Hall IP. Pharmacogenetics and ethnicity: more complexities of personalized prescribing. Am J Respir Crit Care Med 2005; 171: 535-6
45. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002; 1: 300-8
46. Tate SK, Goldstein DB. Will tomorrow's medicines work for everyone? Nat Genet 2004; 36: S34-42
47. Tang H. Confronting ethnicity-specific disease risk. Nat Genet 2006; 38: 13-5
48. Varmus H. Getting ready for gene-based medicine. N Engl J Med 2002; 347: 1526-7
49. Lindsay MA. Finding new drug targets in the 21st century. Drug Discov Today 2005; 10: 1683-7
50. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003; 348: 553-6
51. In Vivo Pharmacology Training Group. The fall and rise of in vivo pharmacology. Trends Pharmacol Sci 2002; 23: 13-8
52. Collis MG. What is the future role of pharmacologists in the pharmaceutical industry? Trends Pharmacol Sci 2006; 27: 126-9
53. Walker MJA, Soh MLM. Challenges facing pharmacology: the in vivo situation. Trends Pharmacol Sci 2006; 27: 125-6
54. Carpenter AE, Sabatini DM. Systematic genome-wide screens of gene function. Nat Rev Genet 2004; 5: 11-22
55. Hardiman G. Microarray platforms-comparisons and contrasts. Pharmacogenomics 2004; 5: 487-502
56. Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55: 425-61
57. Chan LMS, Lowes S, Hirst BH. The ABCs of drug transport in intestine and live: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21: 25-51
58. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; 44: 137-66
59. De Groot MJ. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 2006; 11: 601-6
60. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today 2004; 9: 276-85
61. Kurland L, Lind L, Melhus H. Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol Sci 2005; 26: 443-7
62. Saavedra JM. Studies on genes and hypertension: a daunting task. J Hypertension 2005; 23: 929-32
63. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003; 4: 1-4
64. Gardner SP. Ontologies and semantic data integration. Drug Discov Today 2005; 10: 1001-7
65. Millenson ML. The promise of personalized medicine: a conversation with Michael Svinte. Health Affairs 2006; 25: w54-60
66. Gurwitz D, Lunshof JE, Altman RB. A call for the creation of personalized medicine databases. Nat Rev Drug Discov 2006; 5: 23-6
67. Thornton M, Gladwin A, Payne R, et al. Automation and validation of DNA-banking systems. Drug Discov Today 2005; 10: 1369-75
68. Martin P, Haefeli WE, Martin-Facklam M. A drug database model as a central element for computer-supported dose adjustment within a CPOE system. J Amer Med Inform Assoc 2004; 11: 427-32
69. Orphanoudakis S. HYGEIAnet: the integrated regional health information network of Crete. Stud Health Technol Inform 2004; 100: 66-78
70. Mäkinen M, Forsström J, Äärimaa M, et al. A European survey on the possibilities and obstacles of electronic prescriptions in cross-border healthcare. Telemed J E Health 2006; 12: 484-9
71. British Pharmacological Society and the Physiological Society. Tackling the need to teach integrative pharmacology and physiology: problems and ways forward. Trends Pharmacol Sci 2006; 27: 130-3
72. Farahani P, Levine M. Pharmacovigilance in a genomic era. Pharmacogenomics J 2006; 6: 158-61
73. Psaty BM, Burke SP. Protecting the health of the public: Institute of Medicine recommendations on drug safety. N Engl J Med 2006; 355: 1753-5
74. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24: 619-25
75. Liew C-C, Dzau VJ. Molecular genetics and genomics of heart failure. Nat Rev Genet 2004; 5: 811-25
76. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45
77. Roberts R, Brugada R. Genetics and arrhythmias. Annu Rev Med 2003; 54: 257-67
78. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005; 10: 149-55
79. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. J Amer Med Assoc 2005; 294: 2975-80
80. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006; 46: 498-507
81. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005; 28: 1009-28
82. Vizirianakis IS. Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur J Pharm Sci 2002; 15: 243-50
83. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci 2003; 24: 122-5
84. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J 2005; 5: 221-5
85. Vizirianakis IS. The transformation of pharmacogenetics into pharmacogenomics reinforces personalized medicine towards pharmacotyping for improved patient care. In: Barnes LP, editor. New research on pharmacogenetics. New York: Nova Science Publishers, Inc., 2007: 1-38
86. Cambridge Healthcare Institute. Pharmaceutical genomics glossary & taxonomy: evolving terminology for emerging technologies [online]. Available from URL: http://www.genomicglossaries.com/content/genomics_glossary.asp [Accessed 2007 Aug 14]
87. Guo Y, Shafer S, Weller P, et al. Pharmacogenomics and drug development. Pharmacogenomics 2005; 6: 857-64
88. Guo Y, Weller P, Allard J, et al. Understanding our drugs and our diseases. Proc Am Thorac Soc 2006; 3: 409-12
89. Leon De J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47: 75-85
90. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-54